CIK 0001512762
- Accelerated filer
- Smaller reporting company
Coherus Oncology, Inc.
Sign in to watch- Ticker
- CHRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 273615821
- Phone
- +1 650-649-3530
- Business address
- C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
- Former names
- Coherus BioSciences, Inc., BioGenerics, Inc.
- 3/A Insider 3/A
- 4 Open-market sale Chief Scientific Officer sold 4,250 shares at an average $21.36 ($90,763)
- 4 Exercise or conversion Chief Financial Officer acquired 400 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Scientific Officer sold 6,500 shares at an average $15.29 ($99,397)
- 4 Exercise or conversion Director acquired 8,124 shares (option exercise)
- 4 Open-market sale Chief Scientific Officer sold 2,000 shares at $15.02 ($30,040)
- 4 Open-market sale Chief Scientific Officer sold 4,250 shares at an average $21.47 ($91,252)
- 4 Exercise or conversion Chief Scientific Officer acquired 16,000 shares (option exercise)
- 4 Open-market sale Chief Scientific Officer sold 11,333 shares at an average $29.49 ($334,197)
- 4 Open-market sale President and CEO sold 400 shares at $31.75 ($12,700)
- 4 Open-market sale Director sold 15,000 shares at an average $27.49 ($412,425)
- 4 Open-market sale Chief Scientific Officer sold 18,416 shares at an average $28.71 ($528,689)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Scientific Officer sold 4,250 shares at an average $18.98 ($80,644)
- 4 Open-market sale Chief Scientific Officer sold 11,333 shares at an average $27.39 ($310,393)
- 4 Insider Changes in Ownership
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Director sold 6,373 shares at $33.50 ($213,508)
Page 17 of 20 · 399 filings